Advanced Search

Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2002 June;14(2) > Minerva Biotecnologica 2002 June;14(2):159-64

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology

Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246

Frequency: Quarterly

ISSN 1120-4826

Online ISSN 1827-160X

 

Minerva Biotecnologica 2002 June;14(2):159-64

7th INTERNATIONAL CONFERENCE ON TRANSGLUTAMINASES AND PROTEIN CROSSLINKING REACTIONS
Ferrara (Italy), September 14-17, 2002 

    REVIEWS

Differentiation therapy of cancer. Transglutaminase as differentiative tool

Lenini A., Beninati S.

Department of Biology, University of Rome “Tor Vergata”, Rome, Italy

Differentiation therapy is a new approach to the treatment of advanced or aggressive malignancies and may be significantly efficacious in the treatment of many types of cancer. Several research projects are focused on different approaches to the study of cancer cell differentiation, all of which serve to complement one another. Our experimental address in this field is the identification of new molecules able to induce cancer cell differentiation by enhancing transglutaminase (TGase) activity. Recently, retinoic acid and theophylline appeared particularly promising as inducers of differentiation in cultured melanoma cell lines. This overview will explore the potential mechanism(s) involved in the action of these molecules, evaluating the possibility of their therapeutical applications.

language: English


FULL TEXT  REPRINTS

top of page